Buy



# **MAX Financial Services**

Estimate change

TP change

Rating change

Motilal Oswal values your support in the Asiamoney Brokers Poll 2021 for India Research, Sales, Corporate Access and Trading team. We request your ballot.



Bloomberg	MAXF IN
Equity Shares (m)	345
M.Cap.(INRb)/(USDb)	343.8 / 4.7
52-Week Range (INR)	1050 / 463
1, 6, 12 Rel. Per (%)	3/44/61
12M Avg Val (INR M)	1053

### Financials & Valuations (INR b)

Y/E MARCH	FY21	FY22E	FY23E
Net Premiums	190.2	224.9	272.0
Sh.PAT	5.2	7.1	8.0
NBP gr - unwtd (%)	22.3	21.0	24.0
NBP gr - APE (%)	19.5	20.7	24.3
Premium gr (%)	17.5	18.2	21.0
VNB margin (%)	25.2	26.4	26.8
Op. RoEV (%)	18.5	21.0	22.3
Total AUMs (INRb)	904	1,066	1,246
VNB(INRb)	12.5	15.8	19.9
EV per Share	274.5	325.5	390.8
Valuations		0.0	0.0
P/EV (x)	4.5	3.8	3.2
P/EVOP (x)	29.0	21.6	17.2

### Shareholding pattern (%)

As On	Mar-21	Dec-20	Mar-20
Promoter	17.0	17.3	28.3
DII	51.4	50.9	29.0
FII	23.1	19.7	30.6
Others	8.5	12.2	12.1

FII Includes depository receipts

Steady performance; Non-PAR growth remains robust
Persistency improves; maintains healthy provisioning buffer towards pandemic linked claims

TP: INR1,200 (+20%)

- MAXLIFE continues to demonstrate resilient performance amid a challenging macro environment, led by healthy (36%) APE growth, aided by robust growth in Non-PAR savings and recovery in the ULIP segment. After witnessing robust Protection growth over 1H, the same moderated during 2HFY21.
- Healthy product mix towards high margin segments and strong APE growth aided VNB growth of 44% YoY during 4QFY21. Strong push via the bancassurance channel has aided premium growth, while the proprietary channel is showing healthy traction.
- We expect 22% CAGR in APE growth over FY21-23E, with VNB margin improving to 26.8% by FY23E. This would enable 26% VNB CAGR over FY21-23E, while operating RoEV sustains ~22%. **Maintain Buy.**

### VNB growth steady; persistency recovers further

**CMP: INR996** 

- Gross written premium grew ~21% YoY led by a 36%/40% growth in the first year/single premium, while renewal premium grew ~14%. Shareholder PAT declined 54% YoY to ~INR1.1b in 4QFY21 on higher additional provisions towards COVID-19 death claims.
- Individual APE grew 35% YoY in 4QFY21. Total APE growth stood at 36% YoY, aided by strong trends in Non-PAR savings (143%), with the launch of a new product 'Smart Wealth plan', while ULIP showed recovery trends. Protection growth moderated at 5% YoY as Group Protection fell 17%, while Individual Protection grew 17%. The share of Non-PAR savings increased to 30% in FY21 v/s 18% in FY20. The share of Protection stood at 14% v/s 13% in FY20.
- Absolute VNB growth was healthy at 44% YoY due to strong margin profile and healthy product mix. Margin stood ~24% in 4QFY21 (v/s 22.8% in 4QFY20). Absolute VNB grew 39% YoY in FY21. VNB margin improved sharply to 25.2% in FY21 (v/s 21.6% in FY20).
- On the distribution side, banca APE reported robust trends and grew 41% YoY, while proprietary channel APE witnessed a strong (22%) recovery in 4QFY21. The share of banca improved to 71% in FY21 (v/s 68% in FY20), while the share of proprietary stood at 28% (v/s 31% in FY20).
- MAXLIFE witnessed total net claims of ~INR1.2b in FY21 on account of COVID-19 deaths. It made total provisions of INR3.4b due to a likely adverse COVID-19 experience in FY22, and now holds an excess provision buffer of INR5b on its Balance Sheet. Operating RoEV stands at 18.5% (v/s 20.3% in FY20), impacted by higher COVID-19 provisions.
- Persistency improved with 13th/61st month improving by 100bp/200bp to 84%/54%. In other cohorts, persistency trends remained stable (barring the 49th month). On the cost front, opex-to-GWP ratio declined to 20.7% (v/s 21.7%/20.8% over 9MFY21/FY20).

Research Analyst: Nitin Aggarwal (Nitin.Aggarwal@MotilalOswal.com) | Himanshu Taluja (Himanshu.Taluja@motilaloswal.com)

Alpesh Mehta (Alpesh.Mehta@MotilalOswal.com); Yash Agarwal (Yash.Agarwal@motilaloswal.com)

### Highlights from the management commentary

- In the medium term, the management expects persistency to reflect an upward trajectory. The 13th month persistency can reach up to 86% (v/s 84% currently).
- It expects business growth between 15% and 20% over FY22.
- The Non-PAR segment will continue to remain between 25% and 30% in the total APE mix. It expects a 200-300bp VNB margin improvement over the next 2-3 years.

### Valuation and view

MAXLIFE reported strong operating trends, with premium growth in the Non-PAR business remaining steady, while the ULIP business showed a recovery. VNB margin has improved sharply to ~25.2% in FY21 (360bp YoY improvement), while persistency trends have also improved. Strong push via the bancassurance channel has supported premium growth, while growth is improving gradually in the proprietary channel. We estimate APE growth at 22% CAGR over FY20-23E and VNB margin to improve to 26.8% in FY23E. This would enable 26% VNB CAGR over FY21-23E, while operating RoEV will sustain ~22%. We maintain our Buy rating with a TP of INR1,200/share (3.1x FY23E EV/3.8x FY23E EV after a 20% holding company discount).

<b>Quarterly performance</b>												(INR m)
Policyholder's A/c		FY20 FY21				FY20	FY21E	Var.				
(INR m)	1Q	2Q	3Q	4Q	1Q	2Q	3Q	4Q	F120	FIZIE	4QE	Val.
Gross premium income	26,510	37,810	38,800	58,710	27,510	45,330	46,280	71,060	1,61,836	1,90,180	68,123	4%
Growth (%)	14.3%	14.6%	12.8%	6.4%	3.8%	19.9%	19.3%	21.0%	11.0%	17.5%	16.0%	
Renewal premium	17,400	24,010	24,770	39,820	18,520	29,370	28,800	45,230	1,06,000	1,21,920	45,226	0%
Growth (%)	12.0%	11.3%	10.3%	15.1%	6.4%	22.3%	16.3%	13.6%	12.6%	15.0%	13.6%	
PAT	680	860	1,540	2,314	1,710	260	2,200	1,060	5,394	5,230	2,700	-61%
Growth (%)	NA	NA	NA	NA	151.5%	-69.8%	42.9%	-54.2%	-3.1%	-3.0%	16.7%	
Key metrics (INR m)												
New Business APE	6,850	10,450	10,100	14,090	6,610	11,540	12,250	19,170	42,380	49,570	17,876	7%
VNB	1,340	2,300	2,120	3,210	1,130	3,250	3,500	4,610	8,970	12,490	4,667	-1%
AUM (INR b)	640	650	686	685	730	780	850	904	685	904	905	0%
Key Ratios (%)												
VNB Margin (%)	19.6	22.0	21.0	22.8	17.1	28.2	28.6	24.0	21.6	25.2	26.1	206bp
Solvency ratio (%)	225.0	224.0	220.0	207.0	212.0	207.0	208.0	196.0	207.0	196.0	208.7	1, 270bp

E: MOFSL estimates

**Exhibit 1: Quarterly snapshot** 

Policyholder A /o (IND h)	FY20		FY21				Change (%)			
Policyholder A/c (INR b)	1Q	2Q	3Q	4Q	1Q	2Q	3Q	4Q	YoY	QoQ
Gross premium	26.5	37.8	38.8	58.7	27.5	45.3	46.3	71.1	21	54
First year premium	6.5	10.5	10.0	13.9	6.2	11.3	12.0	18.9	36	57
Renewal premium	17.4	24.0	24.8	39.8	18.5	29.4	28.8	45.2	14	57
Single premium	2.7	3.3	4.0	5.0	2.8	4.7	5.5	7.0	40	27
Shareholder's PAT	0.7	0.9	1.5	2.3	1.7	0.3	2.2	1.1	-54	-52
APE data (INR b)										
PAR	2.3	3.1	2.9	4.2	1.5	1.6	2.1	4.3	1	104
Individual Protection	0.5	0.7	1.0	1.1	0.9	1.3	0.9	1.4	26	65
Group Protection	0.5	0.7	0.4	0.4	0.7	0.7	0.4	0.7	52	76
Non-PAR Savings	1.0	2.4	2.0	2.0	1.2	4.4	4.4	4.8	143	10
ULIP	2.5	3.5	4.1	5.6	2.3	3.3	4.4	8.3	48	89
APE (% of total)									Cha	nge (bp)
PAR	33	30	28	30	22	14	17	22	-783	517
Individual Protection	7	7	10	8	14	11	7	7	-59	38
Group Protection	8	6	4	3	11	6	3	3	36	38
Non-PAR Savings	15	23	20	14	18	38	36	25	1,113	-1,072
ULIP	37	34	40	40	35	29	36	43	340	738
Distribution mix (%)										
Proprietary	33	33	30	29	37	28	27	25	-423	-221
Banca	66	66	69	70	62	71	72	74	423	221
Others	1	1	1	1	1	1	1	1	0	0
Key Ratios (%)										
Operating ratios										
Opex-to-GWP ratio (%)	24.7	23.0	22.7	20.8	21.9	21.6	21.7	20.7	-10	-100
Solvency Ratio	225.0	224.0	220.0	207.0	212.0	207.0	208.0	196.0	-1,100	-1,200
Profitability ratios										
VNB margin	19.6	22.0	21.0	22.8	17.1	28.2	28.6	24.0	127	-452
Persistency ratios										
13th month	85.0	85.0	85.0	83.0	82.0	83.0	83.0	84.0	100	100
25th month	72.0	72.0	72.0	71.0	68.0	69.0	69.0	71.0	0	200
37th month	64.0	65.0	63.0	63.0	61.0	61.0	61.0	63.0	0	200
49th month	60.0	60.0	60.0	59.0	57.0	58.0	57.0	58.0	-100	100
61st month	53.0	53.0	51.0	52.0	52.0	53.0	54.0	54.0	200	0
Key Metrics (INR b)										
VNB	1.3	2.3	2.1	3.2	1.1	3.3	3.5	4.6	44	32
EV	93	97	101	100	107	110	117	118	19	1
AUM	640	650	686	685	730	780	850	904	32	6
Equity Mix (%)	21.0	21.0	22.0	17.0	20.8	21.0	23.1	21.6	459	-148

Please note: Persistency ratios, opex ratio, and EV for 1H, nine months, and 12 months





 As per sum assured, it has a 15.6% market share and is ranked third in the industry.

Source: MOFSL, Company

- A solvency surplus of ~INR13b has been maintained on the Balance Sheet.
- In the medium term, the management expects persistency to reflect an upward trajectory. The 13th month persistency can reach up to 86%.
- MAXLIFE believes in maintaining a balanced product mix. It expects NBP (New Business Premium) growth between 15% and 20% over FY22.
- The Non-PAR segment will continue to remain between 25% and 30% in the product mix as it offers better ability to hedge through the FRA market.
- Protection is a long term growth opportunity for the entire sector. The management's focus is on maintaining prudent pricing in this segment.

### **Operating metrics**

- There might be a price increase in Individual Protection policies. It is also reviewing the price of GTL (Group term plans).
- VNB doubled in the last three years, aided by strong trends in the Non-PAR and Protection segment. Tightening of operating expenses helped in VNB margin improvement.
- MAXLIFE is already carrying provisions of INR5b on its Balance Sheet towards
   COVID-19 death claims. This is nearly 4x the net claims witnessed in FY21.
- Tightening of mortality assumption is based on the rise in COVID-19 cases.
- There was an INR880m hit to VNB in FY21.
- Operating variance of INR800m is due to a tax refund of INR630m.
- VNB margin outlook: Over the next 2-3 years, it sees a 200-300bp upside to VNB margin.
- The new Non-PAR product launched in FY21 aided VNB margin improvement. It has better pricing and new offerings v/s the last product.
- **Dividend policy:** The management sees no need to declare a heavy dividend. It will retain most of the capital for the business to expand.
- It will maintain solvency ratio in the 180-200% range.
- In the new protection product, there was a 5-10% increase in pricing v/s the last product.
- Total gross death claims over FY21 stood ~INR13.49b. The same net of reinsurance is INR10.09b.


### **Distribution channel**


- The management's focus is on promoting the Axis Bank brand and is targeting higher cross-sell to AXSB's customer base.
- It expects Yes Bank's banca share to increase, in line with the growth of MAXLIFE.
- On the distribution front, the management focus remains on pushing Non-PAR and ULIP through partner channels, and traditional policy (PAR) and Protection through its own channels.
- It will continue to invest in growing its proprietary channel.

### **Key exhibits**

Exhibit 1: Share of Non-PAR savings improves to 30%, while Protection at 14% in FY21

Exhibit 2: VNB margin improves to ~25.2%, similar to IPRULIFE levels





Source: MOFSL, Company Source: MOFSL, Company

Exhibit 3: Opex-to-GWP ratio at 21.7%





Exhibit 4: Persistency improves in the 13<sup>th</sup>/61<sup>st</sup> month



Source: MOFSL, Company Source: MOFSL, Company

### Valuation and view

- MAXLIFE has increased its focus on Non-PAR and Protection segments, the share of which has increased to ~44% in FY21 v/s ~16% in FY17 as Protection/Non-PAR savings grew by 40%/58% CAGR over FY17-21.
- The company has one of the most productive agency channels, with an improvement in agent productivity to INR250k in FY20 (v/s INR150k in FY17). The proprietary channel accounted for 28% of total APE. The management will continue to make significant investments in growing its proprietary channel.
- VNB has doubled in the last three years, aided by improvement in high margin products in the total APE mix. VNB margin currently stands at 25% (360bp YoY investment).
- Buy with a TP of INR1,200/share: MAXLIFE reported strong operating trends, with premium growth in the Non-PAR business remaining steady, while the ULIP business showed a recovery. VNB margin has improved sharply to ~25.2% in FY21 (360bp YoY improvement), while persistency trends have also improved. Strong push via the bancassurance channel has supported premium growth, while growth is improving gradually in the proprietary channel. We estimate APE growth at 22% CAGR over FY20-23E and VNB margin to improve to 26.8% in FY23E. This would enable 26% VNB CAGR over FY21-23E, while operating RoEV will sustain ~22%. We maintain our Buy rating with a TP of INR1,200/share (3.1x FY23E EV/3.8x FY23E EV after a 20% holding company discount).


Exhibit 5: Value MAXLIFE at INR1,200 per share

Appraisal value method (INR b)	FY23E	
Embedded value	169	
New business profit	19.9	
Appraisal value	647	
MFS' stake post deal	80%	
MFS' value	518	
MFS' valuation per share (INR)	1,500	
Appraisal value-to-embedded value (x)	3.8	
Holding company discount	20%	
Target price (INR)	1,200	
Implied multiples		
- VNB multiple (x)	24.0	
- EVOP multiple (x)		
Upside	20%	

Source: MOFSL


### **Story in charts**

Exhibit 6: First-year premium grew 36% YoY in 4QFY21, while total gross income premium grew 21%




Source: MOFSL, Company

Exhibit 7: Renewal premium up 14% YoY in 4QFY21




Source: MOFSL, Company

Exhibit 8: Proprietary channel APE grew 9% YoY in FY21




Source: MOFSL, Company

**Exhibit 9: Banca APE rose 24% YoY** 



Source: MOFSL, Company

Exhibit 10: VNB margin stands at 24% as on 4QFY21



Source: MOFSL, Company

Exhibit 11: Solvency ratio stands at 196%



Solvency Ratio (%)

Source: MOFSL, Company

## **Financials and valuations**

Tarketal account (IND as)	EV40	EV4.0	EVO	EV24E	EVOOF	EVANE
Technical account (INR m)	FY18	FY19	FY20	FY21E	FY22E	FY23E
Gross Premiums	1,25,009	1,45,752	1,61,836	1,90,180	2,24,861	2,72,000
Reinsurance Ceded	1,213	1,569	2,049	3,263	3,684	4,520
Net Premiums	1,23,795	1,44,184	1,59,788	1,86,916	2,21,176	2,67,480
Income from Investments	37,574	48,643	21,589	42,061	53,324	58,609
Other Income	346	440	612	714	832	971
Total income (A)	1,61,715	1,93,267	1,81,989	2,29,691	2,75,332	3,27,060
Commission	8,929	9,896	10,244	12,644	14,893	17,958
Operating expenses	16,098	19,274	23,441	26,975	31,674	38,239
Total commission and opex	25,027	29,170	33,685	39,619	46,567	56,197
Benefits Paid (Net)	49,466	57,178	66,222	72,531	90,228	1,10,880
Chg. in reserves	79,043	97,365	66,394	1,06,262	1,25,281	1,44,329
Total expenses (B)	1,53,555	1,83,730	1,66,321	2,18,427	2,62,094	3,11,427
(A) - (B)	8,160	9,536	15,668	11,264	13,239	15,633
Prov. for Tax	1,077	1,299	2,752	1,801	2,152	2,662
Surplus/Deficit	7,083	8,237	12,916	9,463	11,087	12,971
Shareholder's a/c (INR m)	FY18	FY19	FY20	FY21E	FY22E	FY23E
Transfer from technical a/c	3,992	4,402	4,690	4,141	5,574	5,944
Income From Investments	2,178	2,177	2,074	2,106	2,739	3,489
Total Income	6,175	6,604	6,781	6,246	8,313	9,432
Total Expenses	24	377	802	330	372	421
PBT	6,152	6,226	5,978	5,917	7,941	9,011
Prov. for Tax	875	662	585	651	874	991
PAT	5,276	5,564	5,394	5,266	7,067	8,020
Growth	-20%	5%	-3%	-2%	34%	13%
Premium (INR m) and growth (%)	FY18	FY19	FY20	FY21E	FY22E	FY23E
New business prem. – unwtd.	43,486	51,604	55,835	68,264	82,599	1,02,423
New business prem WRP	33,072	40,019	42,380	49,525	59,777	74,308
Renewal premium	81,523	94,148	1,06,002	1,21,916	1,42,262	1,69,577
Total premium – unwtd.	1,25,009	1,45,752	1,61,836	1,90,180	2,24,861	2,72,000
New bus. growth – unwtd.	18.6%	18.7%	8.2%	22.3%	21.0%	24.0%
New business growth - WRP	20.3%	21.0%	5.9%	16.9%	20.7%	24.3%
Renewal premium growth	14.6%	15.5%	12.6%	15.0%	16.7%	19.2%
Total prem. growth – unwtd.	16.0%	16.6%	11.0%	17.5%	18.2%	21.0%
Premium mix (%)	FY18	FY19	FY20	FY21E	FY22E	FY23E
New business – unwtd.						
- Individual mix	91.6%	92.0%	91.9%	91.5%	90.5%	90.0%
- Group mix	8.4%	8.0%	8.1%	8.5%	9.5%	10.0%
New business mix - WRP						
- Participating	44.7%	41.4%	32.2%	31.3%	33.7%	33.7%
- Non-participating	13.9%	16.4%	29.6%	33.1%	29.8%	29.6%
- ULIPs	41.4%	42.2%	38.2%	35.6%	36.5%	36.7%
Total premium mix – unwtd.						
- Participating	57.3%	53.4%	49.0%	43.1%	44.1%	43.0%
- Non-participating	14.2%	15.0%	19.8%	25.3%	24.0%	24.4%
- ULIPs	28.5%	31.5%	31.2%	31.6%	31.9%	32.6%

Note: EPS and EV per share adjusted for MFS stake in MAXLIFE

## **Financials and valuations**

Balance Sheet (INR m)	FY18	FY19	FY20	FY21E	FY22E	FY23E
Sources of Fund						
Share Capital	19,188	19,188	19,188	19,943	19,943	19,943
Reserves And Surplus	7,702	8,478	6,806	8,446	6,920	5,785
Shareholders' Fund	26,989	27,609	25,739	28,106	26,548	25,379
Policy Liabilities	3,10,137	3,81,436	4,54,807	5,79,978	6,34,771	6,94,233
Prov. for Linked Liab.	1,63,050	1,86,738	1,74,210	1,95,666	2,48,564	3,14,376
Funds For Future App.	18,655	22,498	30,962	4,926	5,076	6,198
Current liabilities and prov.	17,841	23,398	20,276	23,318	25,649	28,214
Total	5,49,628	6,59,270	7,17,724	8,47,452	9,60,819	10,94,646
Application of Funds						
Shareholders' inv.	32,146	35,187	32,581	43,985	59,379	80,162
Policyholders' inv.	3,19,238	3,94,173	4,60,484	5,64,469	6,44,180	7,36,148
Assets to cover linked liab.	1,70,981	1,98,619	1,91,642	2,01,224	2,13,297	2,26,095
Loans	2,233	3,265	4,264	6,525	9,983	15,274
Total	5,49,628	6,59,270	7,17,724	8,47,452	9,60,819	10,94,646
Operating ratios (%)	FY18	FY19	FY20	FY21E	FY22E	FY23E
Investment yield	8.3%	9.0%	3.4%	5.8%	6.6%	6.4%
Commissions / GWP	7.1%	6.8%	6.3%	6.6%	6.6%	6.6%
- first year premiums	20.2%	18.1%	17.2%	19.5%	19.1%	18.5%
- renewal premiums	3.0%	2.7%	2.6%	2.6%	2.6%	2.6%
- single premiums	0.1%	1.2%	1.1%	1.0%	1.0%	1.0%
Operating expenses/GWP	12.9%	13.2%	14.5%	14.2%	14.1%	14.1%
Total expense ratio	20.0%	20.0%	20.8%	20.8%	20.7%	20.7%
Claims/NWP	39.9%	39.6%	41.4%	38.8%	40.8%	41.5%
Solvency ratio	275%	242%	207%	209%	197%	192%
Persistency ratios (%)	FY18	FY19	FY20	FY21E	FY22E	FY23E
13th Month	80.0%	83.0%	83.0%	84.0%	85.0%	86.0%
25th Month	72.0%	71.0%	71.0%	71.0%	73.0%	74.0%
37th Month	62.0%	64.0%	63.0%	63.0%	63.5%	64.0%
49th Month	57.0%	58.0%	59.0%	58.0%	59.0%	59.5%
61st Month	53.0%	53.0%	52.0%	54.0%	54.5%	55.0%
Profitability ratios (%)	FY18	FY19	FY20	FY21E	FY22E	FY23E
New business margin (%)	20.2%	21.7%	21.6%	25.2%	26.4%	26.8%
RoE (%)	20.3%	20.4%	20.2%	19.6%	25.9%	30.9%
Operating RoEV	20.6%	21.9%	20.3%	18.5%	21.0%	22.3%
RoEV (%)	13.9%	19.0%	11.6%	18.6%	18.6%	20.1%
Valuation ratios	FY18	FY19	FY20	FY21E	FY22E	FY23E
Total AUMs (INR b)	522	628	685	904	1,066	1,246
EPS (INR)	14.3	15.0	14.5	12.2	16.4	18.6
Value of new business (INR b)	6.6	8.6	9.0	12.5	15.8	19.9
Embedded Value (INR b)	75.1	89.4	99.8	118.3	140.4	168.5
EV Per share (INR)	157.8	187.9	209.7	274.5	325.5	390.8
P/EV (x)	8.0	6.8	6.0	4.6	3.9	3.2
P/EPS (x)	88.5	84.7	87.4	103.9	77.4	68.2
P/EVOP (x)	40.2	33.2	30.2	29.5	22.0	17.5
P/VNB (x)				43.8	34.7	27.5

Note: Valuation ratios adjusted for MFS stake (80%) and holding company discount of 20%

Explanation of Investment Rating					
Investment Rating	Expected return (over 12-month)				
BUY	>=15%				
SELL	<-10%				
NEUTRAL	< - 10 % to 15%				
UNDER REVIEW	Rating may undergo a change				
NOT RATED	We have forward looking estimates for the stock but we refrain from assigning recommendation				

\*In case the recommendation given by the Research Analyst is inconsistent with the investment rating legend for a continuous period of 30 days, the Research Analyst shall within following 30 days take appropriate measures to make the recommendation consistent with the investment rating legend.

The following Disclosures are being made in compliance with the SEBI Research Analyst Regulations 2014 (herein after referred to as the Regulations).

Motilal Oswal Financial Services Ltd. (MOFSL) is a SEBI Registered Research Analyst having registration no. INH000000412. MOFSL, the Research Entity (RE) as defined in the Regulations, is engaged in the business of providing Stock broking services, Investment Advisory Services, Depository participant services & distribution of various financial products. MOFSL is a subsidiary company of Passionate Investment Management Pvt. Ltd.. (PIMPL). MOFSL is a listed public company, the details in respect of which are available on www.motilaloswal.com. MOFSL (erstwhile Motilal Oswal Securities Limited - MOSL) is registered with the Securities & Exchange Board of India (SEBI) and is a registered Trading Member with National Stock Exchange of India Ltd. (NSE) and Bombay Stock Exchange Limited (BSE), Multi Commodity Exchange of India Limited (MCX) and National Commodity & Derivatives Exchange Limited (NCDEX) for its stock broking activities & is Depository participant with Central Depository Services Limited (CDSL) National Securities Depository Limited (NSDL), NERL, COMRIS and CCRL and is member of Association of Mutual Funds of India (AMFI) for distribution of financial products and Insurance Regulatory & Development Authority of India (IRDA) as Corporate Agent for insurance products. Details of associate entities of Motilal Oswal Financial Services Limited are available on the website at http://onlinereports.motilaloswal.com/Dormant/documents/List%20of%20Associate%20companies.pdf

MOFSL and its associate company(ies), their directors and Research Analyst and their relatives may; (a) from time to time, have a long or short position in, act as principal in, and buy or sell the securities or derivatives thereof of companies mentioned herein. (b) be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the company(ies) discussed herein or act as an advisor or lender/borrower to such company(ies) or may have any other potential conflict of interests with respect to any recommendation and other related information and opinions; however the same shall have no bearing whatsoever on the specific recommendations made by the analyst(s), as the recommendations made by the analyst(s) are completely independent of the views of the associates of MOFSL even though there might exist an inherent conflict of interest in some of the stocks mentioned in the research report

MOFSL and / or its affiliates do and seek to do business including investment banking with companies covered in its research reports. As a result, the recipients of this report should be aware that MOFSL may have a potential conflict of interest that may affect the objectivity of this report. Compensation of Research Analysts is not based on any specific merchant banking, investment banking or brokerage service transactions. Details of pending Enquiry Proceedings of Motilal Oswal Financial Services Limited are available on the website at https://galaxy.motilaloswal.com/ResearchAnalyst/PublishViewLitigation.aspx

A graph of daily closing prices of securities is available at <a href="https://www.nseindia.com">www.nseindia.com</a>, <a href="https://www.nseindia.com">www.nseindi MOFSL research activity and therefore it can have an independent view with regards to Subject Company for which Research Team have expressed their views.

### Regional Disclosures (outside India)

This report is not directed or intended for distribution to or use by any person or entity resident in a state, country or any jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject MOFSL & its group companies to registration or licensing requirements within such jurisdictions.

This report is distributed in Hong Kong by Motilal Oswal capital Markets (Hong Kong) Private Limited, a licensed corporation (CE AYY-301) licensed and regulated by the Hong Kong Securities and Futures Commission (SFC) pursuant to the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) "SFO". As per SEBI (Research Analyst Regulations) 2014 Motilal Oswal Securities (SEBI Reg No. INH000000412) has an agreement with Motilal Oswal capital Markets (Hong Kong) Private Limited for distribution of research report in Hong Kong. This report is intended for distribution only to "Professional Investors" as defined in Part I of Schedule 1 to SFO. Any investment or investment activity to which this document relates is only available to professional investor and will be engaged only with professional investors." Nothing here is an offer or solicitation of these securities, products and services in any jurisdiction where their offer or sale is not qualified or exempt from registration. The Indian Analyst(s) who compile this report is/are not located in Hong Kong & are not conducting Research Analysis in Hong Kong.

### For U.S.

Motilal Oswal Financial Services Limited (MOFSL) is not a registered broker - dealer under the U.S. Securities Exchange Act of 1934, as amended (the "1934 act") and under applicable state laws in the United States. In addition MOFSL is not a registered investment adviser under the U.S. Investment Advisers Act of 1940, as amended (the "Advisers Act" and together with the 1934 Act, the "Acts), and under applicable state laws in the United States. Accordingly, in the absence of specific exemption under the Acts, any brokerage and investment services provided by MOFSL, including the products and services described herein are not available to or intended for U.S. persons. This report is intended for distribution only to "Major Institutional Investors" as defined by Rule 15a-6(b)(4) of the Exchange Act and interpretations thereof by SEC (henceforth referred to as "major institutional investors"). This document must not be acted on or relied on by persons who are not major institutional investors. Any investment or investment activity to which this document relates is only available to major institutional investors and will be engaged in only with major institutional investors. In reliance on the exemption from registration provided by Rule 15a-6 of the U.S. Securities Exchange Act of 1934, as amended (the "Exchange Act") and interpretations thereof by the U.S. Securities and Exchange Commission ("SEC") in order to conduct business with Institutional Investors based in the U.S., MOFSL has entered into a chaperoning agreement with a U.S. registered broker-dealer, Motilal Oswal Securities International Private Limited. ("MOSIPL"). Any business interaction pursuant to this report will have to be executed within the provisions of this chaperoning agreement.

The Research Analysts contributing to the report may not be registered /qualified as research analyst with FINRA. Such research analyst may not be associated persons of the U.S. registered broker-dealer, MOSIPL, and therefore, may not be subject to NASD rule 2711 and NYSE Rule 472 restrictions on communication with a subject company, public appearances and trading securities held by a research analyst account.

### For Singapore

In Singapore, this report is being distributed by Motilal Oswal Capital Markets Singapore Pte Ltd ("MOCMSPL") (Co.Reg. NO. 201129401Z) which is a holder of a capital markets services license and an exempt financial adviser in Singapore As per the approved agreement under Paragraph 9 of Third Schedule of Securities and Futures Act (CAP 289) and Paragraph 11 of First Schedule of Financial Advisors Act (CAP 110) provided to MOCMSPL by Monetary Authority of Singapore. Persons in Singapore should contact MOCMSPL in respect of any matter arising from, or in connection with this report/publication/communication. This report is distributed solely to persons who qualify as "Institutional Investors", of which some of whom may consist of "accredited" institutional investors as defined in section 4A(1) of the Securities and Futures Act, Chapter 289 of Singapore ("the SFA"). Accordingly, if a Singapore person is not or ceases to be such an institutional investor, such Singapore Person must immediately discontinue any use of this Report and inform MOCMSPL.

### Specific Disclosures

- MOFSL, Research Analyst and/or his relatives does not have financial interest in the subject company, as they do not have equity holdings in the subject company.
- MOFSL, Research Analyst and/or his relatives do not have actual/beneficial ownership of 1% or more securities in the subject company
- MOFSL, Research Analyst and/or his relatives have not received compensation/other benefits from the subject company in the past 12 months MOFSL, Research Analyst and/or his relatives do not have material conflict of interest in the subject company at the time of publication of research report
- Research Analyst has not served as director/officer/employee in the subject company
  MOFSL has not acted as a manager or co-manager of public offering of securities of the subject company in past 12 months
- MOFSL has not received compensation for investment banking/ merchant banking/brokerage services from the subject company in the past 12 months
- MOFSL has not received compensation for other than investment banking/merchant banking/brokerage services from the subject company in the past 12 months
- MOFSL has not received any compensation or other benefits from third party in connection with the research report
- 10 MOFSL has not engaged in market making activity for the subject company

9 June 2021

The associates of MOFSL may have:

- financial interest in the subject company
- actual/beneficial ownership of 1% or more securities in the subject company
- received compensation/other benefits from the subject company in the past 12 months
- other potential conflict of interests with respect to any recommendation and other related information and opinions.; however the same shall have no bearing whatsoever on the specific recommendations made by the analyst(s), as the recommendations made by the analyst(s) are completely independent of the views of the associates of MOFSL even though there might exist an inherent conflict of interest in some of the stocks mentioned in the research report.
- acted as a manager or co-manager of public offering of securities of the subject company in past 12 months
- be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the company(ies) discussed herein or act as an advisor or lender/borrower to such company(ies)
- received compensation from the subject company in the past 12 months for investment banking / merchant banking / brokerage services or from other than said services.

The associates of MOFSL has not received any compensation or other benefits from third party in connection with the research report

Above disclosures include beneficial holdings lying in demat account of MOFSL which are opened for proprietary investments only. While calculating beneficial holdings, it does not consider demat accounts which are opened in name of MOFSL for other purposes (i.e holding client securities, collaterals, error trades etc.). MOFSL also earns DP income from clients which are not considered in above disclosures.

### **Analyst Certification**

The views expressed in this research report accurately reflect the personal views of the analyst(s) about the subject securities or issues, and no part of the compensation of the research analyst(s) was, is, or will be directly or indirectly related to the specific recommendations and views expressed by research analyst(s) in this report.

#### **Terms & Conditions:**

This report has been prepared by MOFSL and is meant for sole use by the recipient and not for circulation. The report and information contained herein is strictly confidential and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent of MOFSL. The report is based on the facts, figures and information that are considered true, correct, reliable and accurate. The intent of this report is not recommendatory in nature. The information is obtained from publicly available media or other sources believed to be reliable. Such information has not been independently verified and no guaranty, representation of warranty, express or implied, is made as to its accuracy, completeness or correctness. All such information and opinions are subject to change without notice. The report is prepared solely for informational purpose and does not constitute an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments for the clients. Though disseminated to all the customers simultaneously, not all customers may receive this report at the same time. MOFSL will not treat recipients as customers by virtue of their receiving this report.

#### Disclaimer:

The report and information contained herein is strictly confidential and meant solely for the selected recipient and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent. This report and information herein is solely for informational purpose and may not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Nothing in this report constitutes investment, legal, accounting and tax advice or a representation that any investment or strategy is suitable or appropriate to your specific circumstances. The securities discussed and opinions expressed in this report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient. This may not be taken in substitution for the exercise of independent judgment by any recipient. Each recipient of this document should make such investigations as it deems necessary to arrive at an independent evaluation of an investment in the securities of companies referred to in this document (including the merits and risks involved), and should consult its own advisors to determine the merits and risks of such an investment. The investment discussed or views expressed may not be suitable for all investors. Certain transactions -including those involving futures, options, another derivative products as well as non-investment grade securities - involve substantial risk and are not suitable for all investors. No representation or warranty, express or implied, is made as to the accuracy, completeness or fairness of the information and opinions contained in this document. The Disclosures of Interest Statement incorporated in this document is provided solely to enhance the transparency and should not be treated as endorsement of the views expressed in the report. This information is subject to change without any prior notice. The Company reserves the right to make modifications and alternations to this statement as may be required from time to time without any prior approval. MOFSL, its associates, their directors and the employees may from time to time, effect or have effected an own account transaction in, or deal as principal or agent in or for the securities mentioned in this document. They may perform or seek to perform investment banking or other services for, or solicit investment banking or other business from, any company referred to in this report. Each of these entities functions as a separate, distinct and independent of each other. The recipient should take this into account before interpreting the document. This report has been prepared on the basis of information that is already available in publicly accessible media or developed through analysis of MOFSL. The views expressed are those of the analyst, and the Company may or may not subscribe to all the views expressed therein. This document is being supplied to you solely for your information and may not be reproduced, redistributed or passed on, directly or indirectly, to any other person or published, copied, in whole or in part, for any purpose. This report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject MOFSL to any registration or licensing requirement within such jurisdiction. The securities described herein may or may not be eligible for sale in all jurisdictions or to certain category of investors. Persons in whose possession this document may come are required to inform themselves of and to observe such restriction. Neither the Firm, not its directors, employees, agents or representatives shall be liable for any damages whether direct or indirect, incidental, special or consequential including lost revenue or lost profits that may arise from or in connection with the use of the information. The person accessing this information specifically agrees to exempt MOFSL or any of its affiliates or employees from, any and all responsibility/liability arising from such misuse and agrees not to hold MOFSL or any of its affiliates or employees responsible for any such misuse and further agrees to hold MOFSL or any of its affiliates or employees free and harmless from all losses, costs, damages, expenses that may be suffered by the person accessing this information due to any errors and delays.

Registered Office Address: Motilal Oswal Tower, Rahimtullah Sayani Road, Opposite Parel ST Depot, Prabhadevi, Mumbai-400025; Tel No.: 022 71934200/ 022-71934263; Website <a href="https://www.motilaloswal.com">www.motilaloswal.com</a>. CIN no.: L67190MH2005PLC153397.Correspondence Office Address: Palm Spring Centre, 2nd Floor, Palm Court Complex, New Link Road, Malad(West), Mumbai-400 064. Tel No: 022 7188 1000.

Registration Nos.: Motilal Oswal Financial Services Limited (MOFSL)\*: INZ000158836(BSE/NSE/MCX/NCDEX); CDSL and NSDL: IN-DP-16-2015; Research Analyst: INH000000412. AMFI: ARN - 146822; Investment Adviser: INA000007100; Insurance Corporate Agent: CA0579;PMS:INP000006712. Motilal Oswal Asset Management Company Ltd. (MOAMC): PMS (Registration No.: INP000000670); PMS and Mutual Funds are offered through MOAMC which is group company of MOFSL. Motilal Oswal Wealth Management Ltd. (MOWML): PMS (Registration No.: INP000004409) is offered through MOWML, which is a group company of MOFSL. Motilal Oswal Financial Services Limited is a distributor of Mutual Funds, PMS, Fixed Deposit, Bond, NCDs,Insurance Products and IPOs.Real Estate is offered through Motilal Oswal Real Estate Investment Advisors II Pvt. Ltd. which is a group company of MOFSL. Private Equity is offered through Motilal Oswal Private Equity Investment Advisors Pvt. Ltd which is a group company of MOFSL. Research & Advisory services is backed by proper research. Please read the Risk Disclosure Document prescribed by the Stock Exchanges carefully before investing. There is no assurance or guarantee of the returns. Investment in securities market is subject to market risk, read all the related documents carefully before investing. Details of Compliance Officer: Name: Neeraj Agarwal, Email ID: na@motilaloswal.com, Contact No.:022-71881085.

\* MOSL has been amalgamated with Motilal Oswal Financial Services Limited (MOFSL) w.e.f August 21, 2018 pursuant to order dated July 30, 2018 issued by Hon'ble National Company Law Tribunal, Mumbai Bench.